FI3909972T3 - Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä - Google Patents
Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä Download PDFInfo
- Publication number
- FI3909972T3 FI3909972T3 FIEP21155542.0T FI21155542T FI3909972T3 FI 3909972 T3 FI3909972 T3 FI 3909972T3 FI 21155542 T FI21155542 T FI 21155542T FI 3909972 T3 FI3909972 T3 FI 3909972T3
- Authority
- FI
- Finland
- Prior art keywords
- cell
- polypeptide
- sequence
- cancer
- use according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172913 | 2015-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3909972T3 true FI3909972T3 (fi) | 2024-05-03 |
Family
ID=53476720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21155542.0T FI3909972T3 (fi) | 2015-06-19 | 2016-06-20 | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192935B2 (https=) |
| EP (3) | EP3909972B1 (https=) |
| JP (3) | JP7085988B2 (https=) |
| CN (3) | CN108026151B (https=) |
| AU (1) | AU2016277883B2 (https=) |
| CA (1) | CA2989949A1 (https=) |
| DK (2) | DK3909972T5 (https=) |
| ES (2) | ES2870174T3 (https=) |
| FI (1) | FI3909972T3 (https=) |
| HU (1) | HUE054201T2 (https=) |
| PL (1) | PL3310805T3 (https=) |
| PT (1) | PT3310805T (https=) |
| WO (1) | WO2016203048A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4406604A3 (en) | 2015-03-05 | 2024-10-23 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| DK3909972T5 (da) | 2015-06-19 | 2024-08-05 | Sebastian Kobold | Pd1-cd28-fusionsproteiner og disses anvendelse i medicin |
| JP2018520679A (ja) * | 2015-06-29 | 2018-08-02 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 免疫チェックポイントキメラ抗原受容体療法 |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| EP3433269B1 (en) | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| CN107523545A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| AU2017291262A1 (en) * | 2016-06-30 | 2019-01-03 | F. Hoffmann-La Roche Ag | Improved adoptive T-cell therapy |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| JP2020513754A (ja) * | 2016-12-21 | 2020-05-21 | ティーシーアール２ セラピューティクス インク． | がん治療用に操作されたｔ細胞 |
| ES2912408T3 (es) * | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| CN119409836A (zh) | 2017-03-17 | 2025-02-11 | 弗雷德哈钦森癌症中心 | 免疫调节融合蛋白及其用途 |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| JP7654557B2 (ja) * | 2019-03-27 | 2025-04-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法 |
| AU2020315796A1 (en) * | 2019-07-19 | 2022-02-24 | Memorial Hospital For Cancer And Allied Diseases | Fusion polypeptide for immunotherapy |
| CN113832111A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种类外泌体技术用于制备新型溶瘤病毒的方法 |
| CN113832114A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用 |
| IL305795A (en) * | 2021-03-10 | 2023-11-01 | B G Negev Technologies & Applications Ltd At Ben Gurion Univ | Reporter cells expressing chimeric proteins for use in determining the presence and or activity of immune barrier molecules |
| CN115197314B (zh) * | 2021-04-11 | 2025-08-19 | 中国科学院分子细胞科学卓越创新中心 | 一种pd1变体及其用途 |
| JP2024519945A (ja) * | 2021-05-20 | 2024-05-21 | アチェロイス バイオファーマ，インク． | 免疫チェックポイント多価粒子の組成物、および使用方法 |
| WO2023235479A1 (en) * | 2022-06-02 | 2023-12-07 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| CN121057753A (zh) * | 2022-11-14 | 2025-12-02 | 阿奇洛伊斯生物制药公司 | 免疫检查点多价颗粒组合物和使用方法 |
| WO2025212859A1 (en) * | 2024-04-03 | 2025-10-09 | Solid Biosciences, Inc. | Methods and constructs for increasing solid organ transplant survival |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| ZA200807283B (en) | 2008-08-22 | 2009-10-28 | Mechlift Invest Pty Ltd | Data unit for a bin lifting device |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| WO2013062365A2 (ko) * | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| EP2828290B1 (en) | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
| RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CN105940102B (zh) | 2013-08-26 | 2020-02-18 | 海瑞克·亚柏坎 | 抗cd30嵌合抗原受体及其用途 |
| JP2017537622A (ja) | 2014-12-02 | 2017-12-21 | ロジャー・ウィリアムズ・ホスピタル | がんを治療するための方法及び組成物 |
| EP4406604A3 (en) | 2015-03-05 | 2024-10-23 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| DK3909972T5 (da) | 2015-06-19 | 2024-08-05 | Sebastian Kobold | Pd1-cd28-fusionsproteiner og disses anvendelse i medicin |
| KR20180019725A (ko) | 2015-06-23 | 2018-02-26 | 메모리얼 슬로안-케터링 캔서 센터 | 신규의 피디 1 면역 조절제 |
| JP2018520679A (ja) | 2015-06-29 | 2018-08-02 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 免疫チェックポイントキメラ抗原受容体療法 |
| CA2997551A1 (en) | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| JP7123794B2 (ja) | 2015-12-09 | 2022-08-23 | メモリアル スローン ケタリング キャンサー センター | 免疫細胞組成物及びそれを使用する方法 |
| EP3433269B1 (en) | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| AU2017382243A1 (en) | 2016-12-22 | 2019-05-02 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| CN111051349A (zh) | 2017-09-06 | 2020-04-21 | 弗雷德哈钦森癌症研究中心 | Strep-tag特异性嵌合受体及其用途 |
| CN110951718B (zh) * | 2019-12-02 | 2022-09-30 | 吉林凯莱英医药化学有限公司 | 共固定化酶、其制备方法及其应用 |
-
2016
- 2016-06-20 DK DK21155542.0T patent/DK3909972T5/da active
- 2016-06-20 CN CN201680048221.3A patent/CN108026151B/zh active Active
- 2016-06-20 US US15/737,877 patent/US11192935B2/en active Active
- 2016-06-20 CA CA2989949A patent/CA2989949A1/en active Pending
- 2016-06-20 WO PCT/EP2016/064195 patent/WO2016203048A1/en not_active Ceased
- 2016-06-20 CN CN202210834160.0A patent/CN115927474A/zh active Pending
- 2016-06-20 AU AU2016277883A patent/AU2016277883B2/en active Active
- 2016-06-20 EP EP21155542.0A patent/EP3909972B1/en active Active
- 2016-06-20 JP JP2018517487A patent/JP7085988B2/ja active Active
- 2016-06-20 PL PL16736802T patent/PL3310805T3/pl unknown
- 2016-06-20 HU HUE16736802A patent/HUE054201T2/hu unknown
- 2016-06-20 EP EP24156660.3A patent/EP4349854A3/en active Pending
- 2016-06-20 FI FIEP21155542.0T patent/FI3909972T3/fi active
- 2016-06-20 ES ES16736802T patent/ES2870174T3/es active Active
- 2016-06-20 CN CN202210854297.2A patent/CN115925971A/zh active Pending
- 2016-06-20 PT PT167368026T patent/PT3310805T/pt unknown
- 2016-06-20 EP EP16736802.6A patent/EP3310805B1/en active Active
- 2016-06-20 DK DK16736802.6T patent/DK3310805T3/da active
- 2016-06-20 ES ES21155542T patent/ES2976647T3/es active Active
-
2021
- 2021-10-29 US US17/515,250 patent/US12570718B2/en active Active
-
2022
- 2022-03-22 JP JP2022044885A patent/JP7460675B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044396A patent/JP2024073636A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3909972B1 (en) | 2024-02-14 |
| JP7085988B2 (ja) | 2022-06-17 |
| CA2989949A1 (en) | 2016-12-22 |
| AU2016277883A1 (en) | 2018-01-18 |
| PL3310805T3 (pl) | 2021-08-23 |
| JP2022084787A (ja) | 2022-06-07 |
| US20220169699A1 (en) | 2022-06-02 |
| ES2870174T3 (es) | 2021-10-26 |
| CN115927474A (zh) | 2023-04-07 |
| EP3310805B1 (en) | 2021-02-17 |
| WO2016203048A1 (en) | 2016-12-22 |
| CN108026151B (zh) | 2022-07-15 |
| EP4349854A3 (en) | 2024-07-10 |
| JP2018518990A (ja) | 2018-07-19 |
| AU2016277883B2 (en) | 2020-09-17 |
| US12570718B2 (en) | 2026-03-10 |
| EP4349854A2 (en) | 2024-04-10 |
| ES2976647T3 (es) | 2024-08-06 |
| EP3909972A1 (en) | 2021-11-17 |
| DK3909972T5 (da) | 2024-08-05 |
| JP2024073636A (ja) | 2024-05-29 |
| CN108026151A (zh) | 2018-05-11 |
| JP7460675B2 (ja) | 2024-04-02 |
| HUE054201T2 (hu) | 2021-08-30 |
| AU2016277883A8 (en) | 2018-01-25 |
| EP3310805A1 (en) | 2018-04-25 |
| PT3310805T (pt) | 2021-05-19 |
| US11192935B2 (en) | 2021-12-07 |
| DK3909972T3 (da) | 2024-04-29 |
| CN115925971A (zh) | 2023-04-07 |
| US20190010207A1 (en) | 2019-01-10 |
| DK3310805T3 (da) | 2021-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP2016534717A5 (https=) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| Lee et al. | Human γδ T cell subsets and their clinical applications for cancer immunotherapy | |
| AU2015230611B2 (en) | Method for isolating and proliferating self-tumor antigen-specific CD8+ T cells | |
| IL276593A (en) | Improved methods for producing adoptive cell therapies | |
| JP2018518990A5 (https=) | ||
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| Rotolo et al. | CAR-based strategies beyond T lymphocytes: integrative opportunities for cancer adoptive immunotherapy | |
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| FI3227432T3 (fi) | B-solujen kypsymisantigeeniin kohdistuvia kimeerisiä antigeenireseptoreita ja niiden käyttötarkoituksia | |
| JP2016520074A5 (https=) | ||
| HRP20210116T1 (hr) | Poboljšane kompozicije t stanica | |
| EP4424376A3 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| NZ757613A (en) | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy | |
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| MX367787B (es) | Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer. | |
| JP2017504601A5 (https=) | ||
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| Cutmore et al. | Current perspectives on the use of off the shelf CAR-T/NK cells for the treatment of cancer | |
| JP2018504094A5 (https=) | ||
| JP2018520679A5 (https=) | ||
| JP2017535292A5 (https=) |